ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO1013

V-Set and Ig Domain Containing 4 Is Upregulated in Doxorubicin-Induced Kidney Injury Model

Session Information

  • CKD: Pathobiology - II
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2203 CKD (Non-Dialysis): Mechanisms

Authors

  • Han, Sang Youb, Inje University Ilsan Paik Hospital, Goyang, Korea (the Republic of)
  • Ghee, Jungyeon, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea (the Republic of)
  • Cha, Jin Joo, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea (the Republic of)
  • Cha, Dae R., Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea (the Republic of)
Background

V-set Ig domain containing 4 (VSIG4) is related to fibrosis in several diseases. However, the role of VSIG4 in the kidney diseases is still not clear. We investigated the expression of VSIG4 in doxorubicin-induced mice and doxorubicin-induced podocyte injury model.

Methods

Doxorubicin-induced animal model was observed for 4 weeks. In addition, cultured podocytes were treated by doxorubicin.

Results

In doxorubicin-induced model, the levels of urinary albumin and VSIG4 for 24 h were significantly higher in doxorubicin group than control mice: albumin, median, 12.7 μg (IQR, 9.48-13.03) vs. 6.12, (IQR 2.56-9.26), P=0.006; VSIG4, median, 104.1 pg (IQR 66.3-135.1) vs. 46.3 (IQR 40.9-67.2), P=0.006. Interestingly, urinary VSIG4 levels were significantly correlated with urinary albumin levels (r = 0.912, P<0.001). The expression of intrarenal VSIG4 mRNA showed 2.69-fold higher in the doxorubicin mice than the control mice. To confirm expression of VSIG4 protein, the expression of VSIG4 protein was determined by Western blot. It was significantly higher in the doxorubicin mice than the control mice. In cultured podocytes, the expression of VSIG4 mRNA and protein was significantly higher in doxorubicin (1.0 and 3.0 ug/mL) than the control at 12 and 24 hours. The mRNA expression showed 20.7-fold higher in doxorubicin (3.0 ug/mL) group at 24 hours. The protein expression determined by western blot also showed a similar pattern to the mRNA expression.

Conclusion

In conclusion, the expression of VSIG4 was upregulated in the UUO and doxorubicin-induced models. VSIG4 would be involved in the pathogenesis of renal progression in chronic kidney diseases model.